Improving care for patients with chronic heart failure in the community: the importance of a disease management program.
暂无分享,去创建一个
[1] C. O'connor,et al. The benefit of implementing a heart failure disease management program. , 2001, Archives of internal medicine.
[2] K. Akosah,et al. Chronic heart failure in the community: missed diagnosis and missed opportunities. , 2001, Journal of cardiac failure.
[3] R. Lancashire,et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.
[4] D R Jacobs,et al. Trends in Acute Coronary Heart Disease Mortality, Morbidity, and Medical Care From 1985 Through 1997: The Minnesota Heart Survey , 2001, Circulation.
[5] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[6] J. Cutler,et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. , 2000, Circulation.
[7] N. Sheynberg,et al. Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure , 2000, Clinical cardiology.
[8] F. Zannad,et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. , 2000, American heart journal.
[9] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[10] M. Rich,et al. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. , 1999, American heart journal.
[11] D. Baker,et al. Variations in family physicians' and cardiologists' care for patients with heart failure. , 1999, American heart journal.
[12] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[13] L. Erhardt,et al. Cost effective management programme for heart failure reduces hospitalisation , 1998, Heart.
[14] D. DeMets,et al. Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF) , 1997 .
[15] G. Fonarow,et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. , 1997, Journal of the American College of Cardiology.
[16] Y Wang,et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.
[17] E. Philbin,et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.
[18] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .